Surgery Websites
T32 Surgical Oncology »  Faculty Mentors »  Regulatory Sciences »  Brian Shoichet, PhD
Brian Shoichet, PhD

Brian Shoichet, PhD

  • Professor, Pharmaceutical Chemistry
  • Link to Pharmacy Profile/Bio

Contact Information

1700 4th St, #508D
San Francisco, CA 94158
Phone: 415-514-4126
Fax: 415-514-4260
[email protected]
Open Popup
  Institution  
  Degree    
  Dept or School    
  End Date    
  • University of California, San Francisco
  • Ph.D.
  • Graduate Division (Pharmaceutical Chemistry)
  • 1991
  • The Shoichet lab seeks to discover chemical reagents that can illuminate biological problems. A longstanding effort to do so is by exploiting protein structures to predict new reagents and therapeutic leads (structure-based ligand discovery). Two ongoing projects are 1. Developing new computational methods for ligand discovery and 2. Applying these to G-Protein Coupled Receptors (GPCRs), which are the single largest family of signaling receptors in human cells.

    Allied with this effort is an experimental research program that 3. Tests the new methods in well-controlled systems, determining x-ray crystal structures and measuring binding thermodynamics. The experimental program has led to unexpected discoveries, including the observation that many drugs and reagents can form colloidal aggregates in solution. This has led us to investigate 4. How the physical organic chemistry of drugs affects their behavior in vitro and in vivo, influencing drug delivery and formulation.

    A new effort turns the entire structural view on its head, 5. Developing computational methods to relate receptors by the similarity of their ligands, rather than by protein sequence or structure. This changes pharmacological relationships dramatically—targets that would normally be considered sequence neighbors are pushed far apart (because their ligands are dissimilar), whereas other targets that supposedly have nothing to do with one another become neighbors (because their ligands are very similar). Since the new relationships are articulated by ligands, they may be directly tested both on isolated receptors and, increasingly, against model whole organisms, such as zebra fish, C. elegans and mice. This project seeks to discover the integrated chemical circuits through which drugs and reagents affect whole organisms. "
      Award  
      Confired By    
      Date    
  • Society for Biomolecular Sciences Accomplishment Award
  • 2011
  • Topliss Lectureship
  • University of Michigan
  • 2011
  • Abbott Lectureship
  • Yale University
  • 2009
  • Swiss Universities 3e Cycle en Chimie (Lausanne, Bern, Friborg, Geneva)
  • 2008
  • Novartis Chemistry Lecturer (Cambridge, Basel, Vienna, Horsham, Tsukuba, Emeryville)
  • 2006 - 2007
  • Astra Lectureship
  • University of Ottawa
  • 2004
  • Dean’s Award for Teaching Excellence
  • Northwestern University
  • 2001
  • CAREER Award
  • National Science Foundation
  • 1998 - 2003
  • Career Development Award
  • PhRMA Foundation
  • 1997 - 1999
  • Damon Runyon-Walter Winchell Cancer Research Fellow
  • 1993 - 1996
  • Dr. Brian develops new methods for drug discovery using intensive modelling and close collaboration between theory and experiment. By reducing biology to its molecular components and seeking to change how these fit together using novel synthetic molecules we design and by investigating how the biological molecules operate together, both in health and disease. In the past 10 years, he has mentored 10 pre doctorates and 20 post-doctoral trainees, the majority of whom have gone onto research-related careers. He is a preceptor on NIH Training Grants in Biophysics (PI, Matt Jacobson), Chemical Biology (PI, Charly Craik) and Pharmaceutical Sciences (PI Frank Szoka).

    A broad range of project are available for trainees, centered on academic drug discovery, chemical biology, and biophysics.

    Data provided by UCSF Profiles, powered by CTSI
    • A Web-Based Automatic Virtual Screening System
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2004
      -
      Apr 2025
      Principal Investigator
    • Degenerative and Dementing Diseases of Aging
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jan 1981
      -
      Mar 2025
      Co-Investigator
    • Illuminating the Druggable GPCR-ome
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2017
      -
      Aug 2023
      Co-Principal Investigator
    • Development and Testing of New Computational Methods for Ligand Discovery and Mechanism
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 2017
      -
      May 2022
      Principal Investigator
    • Molecular Details of Psychoactive Drug Actions
      Sponsor:
      Sponsor ID:
      Funding Period:
      Mar 2017
      -
      Dec 2021
      Co-Principal Investigator
    • A Specific Mechanism for non-specific inhibition
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 1992
      -
      May 2019
      Principal Investigator
    • Design and Experimental Testing of New Docking Methods
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 1999
      -
      Nov 2018
      Principal Investigator
    • Scalable technologies for illuminating the druggable GPCR-ome
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2014
      -
      Apr 2018
      Co-Principal Investigator
    • Bio-Organic Biomedical Mass Spectrometry Resource
      Sponsor:
      Sponsor ID:
      Funding Period:
      Mar 1982
      -
      May 2015
      Co-Investigator
    • Structure, Function and Inhibition of Beta-Lactamases
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2001
      -
      Feb 2015
      Principal Investigator
    • Resource for Biocomputing, Visualization, and Informatics
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 1976
      -
      Sep 2012
      Co-Investigator
    • Promiscuous and Specific Inhibitors of Cruzain
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2007
      -
      Aug 2008
      Principal Investigator
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 266
    Data provided by UCSF Profiles, powered by CTSI
    1. Shoichet BK, Craik CS. Preparing for the next pandemic. Science. 2023 Nov 10; 382(6671):649-650. View in PubMed
    2. Haas KM, McGregor MJ, Bouhaddou M, Polacco BJ, Kim EY, Nguyen TT, Newton BW, Urbanowski M, Kim H, Williams MAP, Rezelj VV, Hardy A, Fossati A, Stevenson EJ, Sukerman E, Kim T, Penugonda S, Moreno E, Braberg H, Zhou Y, Metreveli G, Harjai B, Tummino TA, Melnyk JE, Soucheray M, Batra J, Pache L, Martin-Sancho L, Carlson-Stevermer J, Jureka AS, Basler CF, Shokat KM, Shoichet BK, Shriver LP, Johnson JR, Shaw ML, Chanda SK, Roden DM, Carter TC, Kottyan LC, Chisholm RL, Pacheco JA, Smith ME, Schrodi SJ, Albrecht RA, Vignuzzi M, Zuliani-Alvarez L, Swaney DL, Eckhardt M, Wolinsky SM, White KM, Hultquist JF, Kaake RM, García-Sastre A, Krogan NJ. Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets. Nat Commun. 2023 09 27; 14(1):6030. View in PubMed
    3. Kunach P, Vaquer-Alicea J, Smith MS, Hopewell R, Monistrol J, Moquin L, Therriault J, Tissot C, Rahmouni N, Massarweh G, Soucy JP, Guiot MC, Shoichet BK, Rosa-Neto P, Diamond MI, Shahmoradian SH. Cryo-EM structure of Alzheimer's disease tau filaments with PET ligand MK-6240. bioRxiv. 2023 Sep 22. View in PubMed
    4. Liu F, Kaplan AL, Levring J, Einsiedel J, Tiedt S, Distler K, Omattage NS, Kondratov IS, Moroz YS, Pietz HL, Irwin JJ, Gmeiner P, Shoichet BK, Chen J. Structure-based discovery of CFTR potentiators and inhibitors. bioRxiv. 2023 Sep 12. View in PubMed
    5. Feng S, Puchades C, Ko J, Wu H, Chen Y, Figueroa EE, Gu S, Han TW, Ho B, Cheng T, Li J, Shoichet B, Jan YN, Cheng Y, Jan LY. Identification of a drug binding pocket in TMEM16F calcium-activated ion channel and lipid scramblase. Nat Commun. 2023 08 12; 14(1):4874. View in PubMed
    6. View All Publications

     

    Site Directory
      X